NovaBiotics Announces Cysteamine Bitartrate (NM002) Included in REMAP-CAP Phase 3 Clinical Trial for Community Acquired Pneumonia – PRNewswire
CONTEXT: Blurring the lines of real-world research and traditional Phase 3, NovaBiotics announce their intravenous cysteamine bitartrate therapy (NM002) has become part of the REMAP-CAP initiative. REMAP-CAP is a global Continue Reading